Sionna Therapeutics announced its PreciSION CF Phase 2a trial failed to meet key endpoints, causing its stock to plunge 91% on August 10, 2026. The trial tested SION-719 combined with Trikafta for cystic fibrosis but did not reduce sweat chloride as hoped. Following the sharp stock drop, Pomerantz LLP launched an investigation into possible securities fraud or unlawful practices by Sionna and its executives. Investors are advised to contact Pomerantz for potential class action participation.
Sionna Therapeutics shares are the subject of this investigation. For readers following the health sector, here is Pluang's market snapshot as of Sep 25, 2026 04:41 WIB: 38 of 100 health stocks rose, 62 fell. Notable movers include Illumina (ILMN) at USD 275.33 with a 7.81% gain and 69% buy order activity, Moderna (MRNA) at USD 194.70 up 6.91% with 87% sell orders, and Ascendis Pharma (ASND) at USD 221.34 down 6.83% with 100% sell orders.
TD SYNNEX posted a record-breaking quarter in Q3 2026 with earnings and revenue surpassing expectations, driven by strong growth in its Hyve Solutions segment and AI infrastructure demand. Despite this, the stock dropped nearly 9% due to a nearly $1 ...
A crypto whale transferred 6,000 Ether (ETH), worth approximately $16.1 million, to five major cryptocurrency exchanges: OKX, Kraken, Gate, Bybit, and Binance. This large transfer places a significant amount of ETH on trading platforms, suggesting th...
Warren Buffett increased his stake in homebuilder Lennar to over 10% immediately after the company missed earnings and lowered its full-year delivery forecast. Despite Lennar's recent weak quarter, Buffett's move signals confidence in the long-term h...
TRON has exceeded $30 trillion in total transaction volume, marking its evolution into a high-throughput settlement network. Daily transactions exceed $30 billion, supported by over 405 million users and 15.6 billion processed transactions, mainly dr...
Costco reported a strong Q4 earnings per share (EPS) of $6.75, surpassing analyst expectations of $6.54, helped by tariff refunds. Although quarterly revenue of $93.87 billion slightly missed the $94.97 billion forecast, net sales rose 11.2% year-ove...
